Core Viewpoint - Far East Pharmaceutical announced the completion of patient enrollment for its innovative temperature-sensitive embolic agent GPN00289 in a clinical study for primary liver cancer in China, highlighting its potential to address the limitations of current treatment methods [1][2] Group 1: Product Development - GPN00289 is recognized as an innovative medical device by the National Medical Products Administration of China [1] - The product combines the advantages of liquid and solid embolization, allowing for effective drug delivery and embolization [1] - The product is expected to be used in conjunction with existing chemotherapy drugs and the company's internal radiotherapy drug, Yttrium-90 microspheres [1] Group 2: Market Strategy - The company aims to actively promote the global registration and development of GPN00289 [2] - There is a strategic focus on creating synergies between GPN00289 and Yttrium-90 microspheres to enhance the treatment of liver cancer [2] - The company is committed to deepening its technological innovation in the global liver cancer treatment field and expanding its nuclear medicine oncology diagnosis and treatment sector [2]
远大医药：创新温度敏感性栓塞剂在中国的注册性临床研究完成全部患者入组